BAM
TEVA icon

Byrne Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Byrne Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Hold
440
– – 0.01% 389
2026
Q1 		$13.3K Sell
440
-120
-21% -$3.86K 0.01% 392
2025
Q4 		$17.5K Hold
560
– – 0.01% 366
2025
Q3 		$11.3K Sell
560
-100
-15% -$1.76K 0.01% 398
2025
Q2 		$11.1K Sell
660
-450
-41% -$7.26K 0.01% 391
2025
Q1 		$17.1K Hold
1,110
– – 0.01% 357
2024
Q4 		$24.5K Sell
1,110
-2,100
-65% -$38.2K 0.02% 265
2024
Q3 		$57.8K Hold
3,210
– – 0.04% 188
2024
Q2 		$52.2K Buy
+3,210
New +$49.4K 0.04% 192
2023
Q4 		– Sell
-200
Closed -$2K – 577
2023
Q3 		$2K Hold
200
– – ﹤0.01% 486
2023
Q2 		$2K Hold
200
– – ﹤0.01% 560
2023
Q1 		$2K Hold
200
– – ﹤0.01% 564
2022
Q4 		$1.82K Hold
200
– – ﹤0.01% 494
2022
Q3 		$2K Hold
200
– – ﹤0.01% 479
2022
Q2 		$2K Hold
200
– – ﹤0.01% 496
2022
Q1 		$2K Hold
200
– – ﹤0.01% 505
2021
Q4 		$2K Buy
+200
New +$1.8K ﹤0.01% 505

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Byrne Asset Management's TEVA Position: Q2 2026 in Review

Byrne Asset Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 440 shares worth $14.9K. The position accounts for 0.01% of the portfolio, ranked #389.

Byrne Asset Management first reported a position in TEVA in Q4 2021 and has held it in 17 quarters since. The position peaked at $57.8K in Q3 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Byrne Asset Management held 440 shares of Teva Pharmaceuticals worth $14.9K as of Q2 2026.
  • Byrne Asset Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up 0.01% of Byrne Asset Management's portfolio in Q2 2026, its #389 holding.
  • Byrne Asset Management first reported a position in Teva Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • Byrne Asset Management's Teva Pharmaceuticals position peaked at $57.8K in Q3 2024.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.